Moderna shares slide as investors weigh recent legal-cost clarity against fresh regulatory uncertainty

Moderna, Inc. (MRNA) is down 7.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied to a post-rally pullback as investors refocus on Moderna’s recently disclosed patent-settlement cash impact and the continuing U.S. regulatory overhang for its standalone flu vaccine. No single, clearly time-stamped new headline specific to today’s session stood out, so profit-taking and sentiment shifts likely played a role.

Details:

Moderna recently disclosed a broad settlement resolving major COVID-19 vaccine-related patent litigation, including a sizable payment and an expected accounting charge, which can pressure near-term sentiment even after removing uncertainty.

The company outlined that the settlement includes a $950 million charge expected in the first quarter of 2026, with additional contingent payments tied to outcomes in related legal matters.

Moderna also received a Refusal-to-File letter from the FDA for its investigational seasonal influenza vaccine (mRNA-1010), leaving U.S. timing uncertain despite Moderna stating the letter did not cite safety or efficacy concerns.

This could be because traders are reassessing the probability and timeline of U.S. flu/franchise expansion after the FDA declined to begin reviewing the BLA in its current form.

Sources:

Moderna (press release), TIME, STAT

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRNA Insider Trading Activity

$MRNA insiders have traded $MRNA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:

STEPHEN HOGE (President) sold 160,009 shares for an estimated $7,814,839
SHANNON THYME KLINGER (Chief Legal Officer) sold 13,885 shares for an estimated $726,046
NOUBAR AFEYAN sold 23,853 shares for an estimated $703,305
ABBAS HUSSAIN sold 504 shares for an estimated $13,910

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$MRNA Hedge Fund Activity

We have seen 257 institutional investors add shares of $MRNA stock to their portfolio, and 398 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 15,741,014 shares (+127.9%) to their portfolio in Q4 2025, for an estimated $464,202,502
CAPITAL WORLD INVESTORS added 12,828,040 shares (+inf%) to their portfolio in Q4 2025, for an estimated $378,298,899
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 6,254,709 shares (-79.7%) from their portfolio in Q4 2025, for an estimated $184,451,368
ALYESKA INVESTMENT GROUP, L.P. added 3,228,531 shares (+inf%) to their portfolio in Q4 2025, for an estimated $95,209,379
BNP PARIBAS FINANCIAL MARKETS added 3,058,933 shares (+279.7%) to their portfolio in Q4 2025, for an estimated $90,207,934
BLACKROCK, INC. added 2,977,816 shares (+10.1%) to their portfolio in Q4 2025, for an estimated $87,815,793
CITADEL ADVISORS LLC removed 1,408,601 shares (-70.9%) from their portfolio in Q4 2025, for an estimated $41,539,643

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$MRNA Analyst Ratings

Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 3 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 02/23/2026
Leerink Partners issued a "Underperform" rating on 11/21/2025
B of A Securities issued a "Underperform" rating on 11/10/2025
UBS issued a "Buy" rating on 10/23/2025
JP Morgan issued a "Underweight" rating on 10/23/2025

To track analyst ratings and price targets for $MRNA, check out Quiver Quantitative's $MRNA forecast page.

$MRNA Price Targets

Multiple analysts have issued price targets for $MRNA recently. We have seen 12 analysts offer price targets for $MRNA in the last 6 months, with a median target of $29.0.

Here are some recent targets:

Edward Tenthoff from Piper Sandler set a target price of $69.0 on 02/23/2026
Salveen Richter from Goldman Sachs set a target price of $41.0 on 02/17/2026
Luca Issi from RBC Capital set a target price of $30.0 on 02/17/2026
Cory Kasimov from Evercore ISI Group set a target price of $35.0 on 02/17/2026
Eliana Merle from UBS set a target price of $34.0 on 01/07/2026
Andrew Tsai from Jefferies set a target price of $30.0 on 12/12/2025
Matthew Harrison from Morgan Stanley set a target price of $28.0 on 12/12/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.